68-3

92/130

gens in the xanthogranulomatous lesions. Pathol Int, 1999; 49: 849-52. 3) Sawada S, Harada K, Isse K, et al: Involvement of Esch-erichia coli in pathogenesis of xanthogranulomatous cholecystitis with scavenger receptor class A and CXCL16-CXCR6 interaction. Pathol Int, 2007; 57: 652-63. 4) Gomi H, Solomkin JS, Schlossberg D, et al: Tokyo Guide-lines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci, 2018; 25: 3-16. 5) Lee JG: Diagnosis and management of acute cholan-gitis. Nat Rev Gastroenterol Hepatol, 2009; 6: 533-41. 6) Kwon AH, Matsui Y, Uemura Y: Surgical procedures and histopathologic findings for patients with xanthogran-ulomatous cholecystitis. Journal of the American College of Surgeons, 2004; 199: 204-10. 7) Kujiraoka M, Kuroda M, Asai K, et al: Comprehensive Diagnosis of Bacterial Infection Associated with Acute Cholecystitis Using Metagenomic Approach. Front Microbiol, 2017; 8: 685. 8) Matyjas T, Kaczka K, Witas H, Ploszaj T, Matyjas K, 288Pomorski L: Cholelithiasis - always infected? Polski przeglad chirurgiczny, 2017; 89: 23-6. 9) Malek RS, Greene LF, DeWeerd JH, Farrow GM: Xanthogranulomatous pyelonephritis. British journal of urology, 1972; 44: 296-308.10) Qualman SJ, Gupta PK, Mendelsohn G: Intracellular Escherichia coli in urinary malakoplakia: a reservoir of infection and its therapeutic implications. American journal of clinical pathology, 1984; 81: 35-42.11) Nowak P, Paluchowska P: Acinetobacter baumannii: biology and drug resistance - role of carbapenemases. Folia histochemica et cytobiologica, 2016; 54: 61-74.12) Tevell S, Hellmark B, Nilsdotter-Augustinsson A, Soderquist B: Staphylococcus capitis isolated from prosthetic joint infections. Eur J Clin Microbiol Infect Dis, 2017; 36: 115-22.13) Kloos WE, Musselwhite MS: Distribution and persistence of Staphylococcus and Micrococcus species and other aerobic bacteria on human skin. Applied microbiology, 1975; 30: 381-5.